Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Finasteride wins 1 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both Finasteride and Tamoxifen (Nolvadex) have evidence — compare verdict strength side-by-side.
1 mg once daily for male pattern hair loss (Propecia); 5 mg once daily for benign prostatic hyperplasia (Proscar). A prescription drug — use under a clinician.
any
Oral tablet (1 mg for hair, 5 mg for BPH)
Approved (oncology) / off-label (male) — clinician-directed. For ER-positive breast cancer the standard adjuvant dose is 20 mg once daily for 5-10 years. For off-label male gynecomastia, the randomized trials used roughly 10-20 mg daily (10 mg/day prophylactically alongside an antiandrogen, 20 mg/day to treat established gynecomastia). For idiopathic male infertility, the trials typically used 20 mg/day. Bodybuilding 'post-cycle therapy' commonly uses 10-40 mg/day tapered — a use with no controlled-trial evidence. There is no FDA-approved male dose.
any
Tamoxifen citrate tablets (approved for breast cancer; off-label in men)
3-12 months to visible effect
Months to years
Throughout use; sometimes persistent
Throughout use
Years
Weeks to months
Weeks to a few months
Throughout use
Finasteride in the treatment of men with androgenetic alopecia.
Journal of the American Academy of Dermatology (1998) · Rct · n=1553
Pivotal double-blind randomized, placebo-controlled trials of finasteride 1 mg/day for male pattern hair loss
Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia.
European journal of dermatology : EJD (2002) · Rct · n=1553
Five-year placebo-controlled extension of the pivotal Phase III hair-loss trials
The impact of monotherapies for male androgenetic alopecia: A network meta-analysis study.
Journal of cosmetic dermatology (2024) · Meta analysis
Network meta-analysis of monotherapies for male androgenetic alopecia
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
Lancet (2011) · Meta analysis
EBCTCG patient-level meta-analysis of randomized adjuvant-tamoxifen trials; ER-positive disease cohort n=10,645
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
J Natl Cancer Inst (1998) · Rct · n=13388
NSABP P-1: randomized, placebo-controlled prevention trial of 20 mg/day tamoxifen for 5 years in 13,388 women at increased breast-cancer risk
A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia.
Clin Genitourin Cancer (2012) · Rct · n=176
Randomized multicenter trial in 176 men on bicalutamide monotherapy for prostate cancer: reactive tamoxifen 20 mg/day (arm A) vs prophylactic tamoxifen 10 mg/day started with bicalutamide (arm B)
Finasteride has a higher evidence score (5.5/10 vs 5.2/10) and wins in 1 of 3 categories.
No known interactions between Finasteride and Tamoxifen (Nolvadex) have been documented in our database. However, always consult a healthcare provider before combining supplements.